Mounjaro (Tirzepatide) and Bone Density: What the UK Evidence Shows

Does Mounjaro (tirzepatide) cause bone loss?

Short answer: it may cause a modest fall in bone mineral density, but the tirzepatide-specific evidence is thin and conflicting — and what change there is appears driven mainly by rapid weight loss, not by a proven toxic effect of the drug. Mounjaro is the brand name for tirzepatide, and whenever the body sheds a large amount of weight quickly, some bone and muscle is lost alongside the fat. The honest headline, though, is that we simply have far less bone data for tirzepatide than for semaglutide.

That matters because tirzepatide is a newer and different medicine. Much of the reassurance and the caution you will read online is quietly borrowed from the semaglutide evidence base — the same swap this article works hard to avoid. Where a claim rests on semaglutide or on the general weight-loss literature rather than on tirzepatide itself, we say so.

Why might tirzepatide affect bone differently from Ozempic and Wegovy?

Because tirzepatide is a dual GIP/GLP-1 receptor agonist, and the extra GIP action may actually favour bone. Semaglutide (in Ozempic and Wegovy) works on the GLP-1 receptor alone; tirzepatide adds glucose-dependent insulinotropic polypeptide (GIP). In laboratory work, GIP receptor signalling has been shown to stimulate bone-building osteoblasts and reduce bone-resorbing osteoclast activity, pointing towards bone formation rather than loss Gut-Derived Peptide Hormone Analogues review, Clinical Medicine Insights: Endocrinology and Diabetes, 2024.

The important caveat: this evidence is largely preclinical (mostly rodent), with only preliminary human data. So it is a reason not to assume tirzepatide is worse for bone than semaglutide — not proof that it protects the skeleton in people losing weight.

What does the tirzepatide-specific bone evidence actually show?

Very little of it measures bone directly, and none of it is a randomised bone-density trial. Here is what exists, from most to least reassuring:

• Muscle is relatively preserved. In the SURMOUNT-1 body-composition substudy, about 74% of the weight lost on tirzepatide was fat and 26% was lean mass — a similar split to placebo SURMOUNT-1 body composition, Diabetes, Obesity and Metabolism, 2025. Crucially, that study did not measure bone density at all — lean mass explicitly excluded bone. A 2025 systematic review likewise concluded tirzepatide preserves muscle relative to total weight lost, and did not examine bone Tirzepatide and skeletal muscle systematic review, Cureus, 2025.
• A matched cohort found small BMD declines — but pooled the two drugs. A 2026 study in JCEM of 255 GLP-1 users matched to 255 controls found both groups lost bone at the hip and femoral neck over a median 17 months, with weight loss the driver; among people without diabetes the medication group lost slightly more total-hip bone (−1% versus −0.6%). This study combined semaglutide and tirzepatide and gave no drug-specific breakdown, so it cannot be pinned to tirzepatide alone Liu et al., JCEM, 2026.
• A large database flagged a signal — but it is observational. More on that below.
• A mouse study caused bone loss directly. In a diabetic (db/db) mouse model, tirzepatide reduced bone mass through a gut-microbiome route, and the authors could not separate the drug's receptor effect from weight loss Chen et al., Journal of Orthopaedic Translation, 2025. This is preclinical and may not translate to humans.

Does Mounjaro increase your risk of osteoporosis or fractures?

One large real-world study raised a flag, but it is observational and cannot prove cause. A 2025 retrospective cohort using the TriNetX database (459,886 eligible patients, 66,329 matched per group) found tirzepatide users had a 44% higher risk of a composite of new-onset osteoporosis or fragility fracture than users of other GLP-1 medicines (hazard ratio 1.44, 95% CI 1.22–1.69) TriNetX cohort, Diabetes Research and Clinical Practice, 2025.

The internal pattern is what makes it worth mentioning: against non-users, tirzepatide carried a raised risk (HR 1.48) while other GLP-1 medicines did not (HR 1.07). But three things temper it. The follow-up was only 14 months; "new-onset osteoporosis" in a claims database largely means a coded diagnosis, so differences in how often tirzepatide versus other-drug patients were scanned and coded between 2022 and 2024 could explain much of the gap; and the two groups differ in ways matching cannot fully fix. For contrast, pooled randomised trials of GLP-1 medicines in type 2 diabetes have, if anything, been associated with a slightly lower fracture risk GLP-1 fracture network meta-analysis, Osteoporosis International, 2018.

Is it the drug or the weight loss affecting my bones?

On current evidence, mostly the weight loss. Bone is living tissue that adapts to the load placed on it, and losing a large amount of weight quickly reduces that load, shifts hormones and can open nutritional gaps — all of which signal bone to remodel down. This is the mechanism we cover in depth in our guides to Ozempic and bone loss and Wegovy and bone density, and it applies to any medication or diet that produces rapid loss.

The practical upshot is encouraging: if the skeleton responds to how weight is lost rather than to a poison in the drug, then the loss is largely preventable with the right support.

Who is most at risk of bone loss on Mounjaro?

The groups with the least reserve to spare: postmenopausal women, people over 40, and anyone who already has low bone density. After the menopause, falling oestrogen already accelerates bone turnover, so a second downward pressure from rapid weight loss matters more. People with type 2 diabetes are harder to place: the preclinical bone-loss signal came from a diabetic mouse model and the observational cohort was in a diabetes-and-obesity population, yet the one human bone-density study found its slightly greater loss in people without diabetes. On current evidence, diabetes status neither clearly sharpens nor softens the picture.

None of this means Mounjaro is unsafe for these groups. It means they have the most to gain from knowing their baseline before assuming their bones are fine.

How can you protect your bones while taking Mounjaro?

The steps with the best evidence across the weight-loss field are resistance exercise and protecting muscle — and Mounjaro's relative muscle preservation is a head start. Because muscle pulls on bone and helps maintain it, the fact that tirzepatide tends to spare lean mass is genuinely good news for the skeleton. Build on it:

• Resistance training (weights, bands, bodyweight) 2–3 times a week to load muscle and bone.
• Weight-bearing activity — walking, stairs, dancing.
• Adequate protein to defend lean mass during weight loss.
• Calcium and vitamin D sufficiency — helpful, though not a complete safeguard on their own.

Our practical guide to protecting your bones on Mounjaro, Wegovy and Ozempic walks through this in more detail.

Should you have a bone density scan before and during Mounjaro?

If you are postmenopausal, over 40, or already have low bone density, a baseline scan before or early in treatment is a sensible precaution — and tirzepatide's open-ended treatment horizon strengthens the case. Unlike some weight-management appraisals, NICE TA1026 does not cap tirzepatide at two years; it recommends it above a BMI threshold with a weight-related comorbidity and sets no fixed two-year time limit (though it does include a six-month review of whether treatment is working) NICE TA1026, 2024. Treatment that can run for years is exactly the situation where a single baseline measurement, repeated over time, earns its keep.

Why a radiation-free REMS scan suits repeat monitoring

Standard DEXA scans use a small dose of X-ray radiation, which makes frequent re-scanning less appealing. REMS (Radiofrequency Echographic Multi Spectrometry) is radiation-free, so it can be repeated safely across a long course of treatment to track change — precisely what monitoring on a weight-loss injection calls for. You can book a radiation-free bone health assessment or read more about our bone health assessment.

Two honest caveats. NICE TA1026 does not include any bone density monitoring — that is a matter of fact. And there is no routine NHS bone-monitoring programme for people on weight-loss injections; whether that is a gap is a judgement, and Screen My Bones considers it one given the emerging data — but that is our view, not a NICE position. Knowing your bone status simply puts you in control of a question the standard pathway does not currently ask.

---

This article is part of our weight-loss medications and bone health series. For the sister drugs, see Ozempic and bone loss and Wegovy and bone density.